Halozyme Therapeutics, Inc. (NASDAQ:HALO)

CAPS Rating: 3 out of 5

A biopharmaceutical company dedicated to the development and commercialization of recombinant human enzymes for the drug delivery, palliative care, oncology and infertility markets.

Recs

1
Player Avatar Momentum21 (98.13) Submitted: 8/7/2012 10:22:27 AM : Outperform Start Price: $9.75 HALO Score: -38.53

In the red on CAPS, green in the Fund. When HALO comes back around the $9.00 way I will re-assess the situation. Boo YAH : )

Featured Broker Partners


Advertisement